American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Investing

Cleo Commences U.S. Regulatory Process with FDA

by admin June 27, 2024
June 27, 2024
Cleo Commences U.S. Regulatory Process with FDA

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce progress in its regulatory strategy for its first commercial product, the pre-surgical triage test.

Highlights

  • Initial pre-submission meeting held with the U.S. Food & Drug Administration (FDA) where CLEO outlined its submission framework and clinical plan
  • Positive feedback from FDA provides confidence in CLEO’s U.S. regulatory strategy
  • Clinical trial design receives Institutional Review Board (IRB) approval in both U.S. and Australia

Commencement of U.S. Regulatory Process

CLEO has completed an initial pre-submission meeting with the U.S. Food and Drug Administration (FDA) where the Company outlined its submission framework and clinical plan for its ovarian cancer detection blood test. The pre-submission meeting is designed to permit CLEO to receive early guidance from FDA review teams prior to an eventual application submission.

The meeting was interactive with the FDA providing constructive and positive feedback on CLEO’s approach to obtaining regulatory approval in the U.S. for its ovarian cancer detection blood test. This outcome provides confidence that CLEO’s clinical trial designs and strategic direction are appropriately aligned with FDA requirements.

Early interaction with the FDA is important as a part of CLEO’s U.S. market access strategy for a number of reasons, as the guidance outcomes allow CLEO to:

  • Refine its clinical trial design to maximise resourcing and quality of data;
  • Reduce the possibility of rework;
  • Shorten the potential timeframe to application submission; and
  • Operate with an open and transparent approach.

CLEO is pursuing expedited FDA approval for its first ovarian cancer detection product – the pre-surgical Triage test – via the 510(k) application pathway. This approach provides the quickest pathway to achieve regulatory approval for devices that achieve ‘substantial equivalence’ to an existing predicate.

Clinical Trial Activity

CLEO’s clinical trial design has now been reviewed and approved in both the U.S. and Australia. Institutional Review Board (IRB) approval is a legal requirement for any clinical trial, to ensure trial activities are ethically sound and compliant with federal regulations.

Trial sites are being formally contracted, and patient recruitment is to commence shortly. CLEO is working with U.S.-based Contract Research Organization (CRO), Lindus Health to manage the international arm of the trial.

Click here for the full ASX Release

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Sarama Completes Tranche 1 Equity Placement and ASX Cleansing Notice
next post
Why Europe’s youth are flirting with the far-right

Related Posts

Brent crude oil price forecast: what is the...

November 14, 2024

Chris Vermeulen: Bullish on Gold, Silver and Miners,...

July 16, 2024

Strong Intercepts Confirm Significant Production Potential at Gould’s...

June 27, 2024

USD/KRW forecast: Here’s why Korean may rebound to...

December 27, 2024

Walmart stock price is firing on all cylinders:...

November 27, 2024

Westpac share price slipped after earnings: time to...

May 5, 2025

Here’s why the Bovespa Index and Brazilian real...

December 18, 2024

First Results Returned from Link Zone Drilling Confirm...

May 22, 2024

Here’s why the DAX index has surged to...

December 6, 2024

BP8 Sources Bird’s Nest Products from Chinese State-Owned...

June 7, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Interview: Strategic location gives Brazil Potash cost advantage in domestic fertiliser market, says CEO Matt Simpson

      June 1, 2025
    • Canada’s Q1 GDP expands by 2.2%, driven by exports spike ahead of potential US tariffs

      June 1, 2025
    • President Trump to host farewell for Elon Musk as DOGE leader steps away

      June 1, 2025
    • UK’s digital banks face divergent fortunes: Starling stumbles, Monzo and Revolut soars

      June 1, 2025
    • Trump wants Apple to shift iPhone production from India to the US: here’s what it means

      May 18, 2025

    Categories

    • Business (3,002)
    • Investing (2,453)
    • Latest News (1,994)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved